Jade Biosciences, INC. 8-K Filing
Ticker: JBIO · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1798749
Sentiment: neutral
Filing Stats: 1,454 words · 6 min read · ~5 pages · Grade level 13.5 · Accepted 2025-12-15 07:11:11
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share JBIO The Nasdaq Capital M
- $14.00 — are (the "Common Stock"), at a price of $14.00 per Share. The aggregate gross proceeds
- $45 m — cement are expected to be approximately $45 million, before deducting offering expens
Filing Documents
- d90753d8k.htm (8-K) — 36KB
- d90753dex101.htm (EX-10.1) — 171KB
- d90753dex102.htm (EX-10.2) — 87KB
- d90753dex991.htm (EX-99.1) — 9KB
- 0001193125-25-318436.txt ( ) — 504KB
- jbio-20251213.xsd (EX-101.SCH) — 3KB
- jbio-20251213_lab.xml (EX-101.LAB) — 19KB
- jbio-20251213_pre.xml (EX-101.PRE) — 12KB
- d90753d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Securities Purchase Agreement, dated December 13, 2025, by and between Jade Biosciences, Inc. and the purchaser party thereto 10.2 Registration Rights Agreement, dated December 13, 2025, by and between Jade Biosciences, Inc. and the purchaser party thereto 99.1 Press Release, dated December 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the Securities and Exchange Commission..
Forward-Looking Statements
Forward-Looking Statements Jade cautions you that statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or continue" and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the expected proceeds, completion and timing of the Private Placement and the anticipated use of proceeds therefrom. Actual results may differ from those set forth in this Current Report on Form 8-K due to the risks and uncertainties inherent in our business, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Private Placement and other risks described in our prior press releases and filings with the SEC, including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Jade Biosciences, Inc. Date: December 15, 2025 By: /s/ Bradford Dahms Name: Bradford Dahms Title: